PRECLINICAL RESEARCH OF THE NEW PREPARATION CALLED "STAPHYLOLEIKIN"
There has been carried out preclinical research of the specific cytokine preparation “Staphyloleikin”, obtained by the original technology from the antistaphylococcal human immunoglobulin production wastes. The preparation specific activity was studied in hypersensitivity transfer test of the delayed type, registered with the help of the reaction of conglomeration of the mice leukocytes with staphylococcal protein A presence. It has been demonstrated that “Staphyloleikin” induces anti-staphylococcal cellular immunity, does not cause pro-inflammatory reaction, and does not possesses myelopoiesis effect. While studying the preparation acute and chronic toxicity on guinea pigs and white mice no signs of toxicity in animals have been revealed. The prospects of using “Staphyloleikin” for treatment of cornea ulcers has been demonstrated on the model of staphylococcal purulent keratitis in rabbits. The preclinical research provides an appropriate opportunity of the use of “Staphyloleikin” as a means of prevention and treatment.